The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1718
ISSUE 1718
December 23, 2024
Issue 1718
- In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists
- Elafibranor (Iqirvo) for Primary Biliary Cholangitis
- Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
- Clonidine Oral Suspension (Onyda XR) for ADHD
- Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease
- In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists
December 23, 2024 (Issue: 1718)
The package inserts of the GLP-1 receptor agonists
dulaglutide (Trulicity), exenatide (Byetta, Bydureon
BCise), liraglutide (Saxenda, Victoza), and semaglutide
(Ozempic, Rybelsus, Wegovy) and the dual glucosedependent
insulinotropic polypeptide...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.